MedTrace Logo

Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

NCT00186381 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-07-27

No results posted yet for this study

Summary

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

Conditions

  • Leukemia, Myelocytic, Acute
  • Leukemia
  • Blood and Marrow Transplant (BMT)

Interventions

PROCEDURE

high dose chemotherapy then autologous hematopoietic cell transplant

Sponsors & Collaborators

Principal Investigators

  • Laura Johnston · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-11-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186381 on ClinicalTrials.gov